Alofanib
| CAS No. | 1612888-66-0 | Cat. No. | BCP31905 |
| Name | Alofanib | ||
| Synonyms | RPT835; RPT-835; RPT 835; | ||
| Formula | C19H15N3O6S | M. Wt | 413.40 |
| Description | Alofanib, also known as RPT835, is a potent and selective allosteric inhibitor of FGFR2 with potential anticancer activity. Alofanib blocks the extracellular part of the receptor and prevents its binding with the ligand. Alofanib suppressed proliferation of endothelial cells, their migration activity, and ability to form vessellike structures in vitro and significantly decreased the number of microvessels in Matrigel implant and in ovarian cancer (SKOV-3) xenograft in vivo. RPT835 potently inhibited growth of KATO III gastric cancer cells expressing FGFR2, with GI50 value of 10 nmol/L. | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase | ||
| Targets | FGFR | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.